BR112012006644A2 - composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit - Google Patents
composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kitInfo
- Publication number
- BR112012006644A2 BR112012006644A2 BR112012006644A BR112012006644A BR112012006644A2 BR 112012006644 A2 BR112012006644 A2 BR 112012006644A2 BR 112012006644 A BR112012006644 A BR 112012006644A BR 112012006644 A BR112012006644 A BR 112012006644A BR 112012006644 A2 BR112012006644 A2 BR 112012006644A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorder
- compound
- neurotransmitter
- kit
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24514809P | 2009-09-23 | 2009-09-23 | |
PCT/US2010/050079 WO2011038162A1 (en) | 2009-09-23 | 2010-09-23 | Pyrido(3,4-b)indoles and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012006644A2 true BR112012006644A2 (pt) | 2019-09-24 |
Family
ID=43796210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012006644A BR112012006644A2 (pt) | 2009-09-23 | 2010-09-23 | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit |
Country Status (8)
Country | Link |
---|---|
US (2) | US20130137705A1 (pt) |
EP (1) | EP2480079A4 (pt) |
JP (1) | JP5791611B2 (pt) |
CN (1) | CN102711467A (pt) |
AU (1) | AU2010298167B2 (pt) |
BR (1) | BR112012006644A2 (pt) |
CA (1) | CA2775129A1 (pt) |
WO (1) | WO2011038162A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
US8546381B2 (en) | 2008-03-24 | 2013-10-01 | Medivation Technologies, Inc. | Bridged heterocyclic compounds and methods of use |
CA2719412A1 (en) | 2008-03-24 | 2009-10-01 | Medivation Technologies, Inc. | Pyrido[3,4-b]indoles and methods of use |
US8569287B2 (en) | 2008-10-31 | 2013-10-29 | Medivation Technologies, Inc. | Azepino[4,5-B]indoles and methods of use |
CN102271508B (zh) | 2008-10-31 | 2015-04-29 | 梅迪维新技术公司 | 含有刚性部分的吡啶并[4,3-b]吲哚类化合物 |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
JP5766614B2 (ja) | 2009-01-09 | 2015-08-19 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 神経新生促進化合物 |
US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
AU2010282990B2 (en) | 2009-04-29 | 2015-11-05 | Medivation Technologies, Inc. | Pyrido [4, 3-b] indoles and methods of use |
AU2010242910B2 (en) | 2009-04-29 | 2015-11-12 | Medivation Technologies, Inc. | Pyrido [4,3-b] indoles and methods of use |
AU2010298166B2 (en) | 2009-09-23 | 2015-09-17 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
CA2775216A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Bridged heterocyclic compounds and methods of use |
CN102724875B (zh) | 2009-09-23 | 2015-05-27 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚化合物及其使用方法 |
WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
WO2011103433A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
JP6126528B2 (ja) * | 2010-07-07 | 2017-05-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 神経新生促進化合物 |
WO2012112963A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
WO2012112965A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
CN103476417A (zh) | 2011-02-18 | 2013-12-25 | 梅迪维新技术公司 | 治疗糖尿病的化合物和方法 |
WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
WO2014031986A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
WO2015070234A2 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective compounds and use thereof |
WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
CN104839184A (zh) * | 2015-04-18 | 2015-08-19 | 广东中迅农科股份有限公司 | 含有氯吡嘧磺隆和氯氨吡啶酸以及烟嘧磺隆的农药组合物 |
WO2019090000A1 (en) | 2017-11-02 | 2019-05-09 | California Institute Of Technology | Expression of neuropeptides |
US11458129B2 (en) * | 2017-11-02 | 2022-10-04 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2642438A (en) * | 1949-07-15 | 1953-06-16 | Hoffmann La Roche | Pyridindoles and method of manufacture |
GB721171A (en) * | 1951-04-30 | 1954-12-29 | Bayer Ag | Derivatives of ª‰- and ª†- carbolines |
JPS3922979B1 (pt) * | 1962-04-10 | 1964-10-15 | ||
JPS3920857B1 (pt) * | 1962-05-17 | 1964-09-24 | ||
JPS412713B1 (pt) * | 1963-08-30 | 1966-02-21 | ||
US4754038A (en) * | 1987-02-26 | 1988-06-28 | American Home Products Corporation | Carboline histamine H1 antagonists |
WO1995007294A1 (en) * | 1993-09-09 | 1995-03-16 | Scios Nova Inc. | Pseudo- and non-peptide bradykinin receptor antagonists |
US5817756A (en) * | 1993-09-09 | 1998-10-06 | Scios Inc. | Pseudo- and non-peptide bradykinin receptor antagonists |
WO1995024200A1 (en) * | 1994-03-11 | 1995-09-14 | Eli Lilly And Company | Method for treating 5ht2b receptor related conditions |
US5688807A (en) * | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
EP0823909B1 (en) * | 1995-05-05 | 2002-09-11 | British Technology Group Inter-Corporate Licensing Limited | Novel heterocyclic chemistry |
GB9604996D0 (en) * | 1996-03-08 | 1996-05-08 | Black James Foundation | Benzodiazonine derivatives |
WO1999025340A1 (en) * | 1997-11-14 | 1999-05-27 | Eli Lilly And Company | Treatment for alzheimer's disease |
FR2771095B1 (fr) * | 1997-11-14 | 1999-12-17 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
KR100588249B1 (ko) * | 1997-12-25 | 2006-06-13 | 메이지 세이카 가부시키가이샤 | 테트라하이드로벤즈인돌 유도체 |
FR2796644B1 (fr) * | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
UA74826C2 (en) * | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
US20060235012A1 (en) * | 2003-06-16 | 2006-10-19 | Chroma Therapeutics Limited | Carboline and betacarboline derivatives for use as hdac enzyme inhibitors |
US7872133B2 (en) * | 2003-06-23 | 2011-01-18 | Ono Pharmaceutical Co., Ltd. | Tricyclic heterocycle compound |
JP4734119B2 (ja) * | 2004-02-12 | 2011-07-27 | 田辺三菱製薬株式会社 | インダゾール化合物及びその医薬用途 |
WO2006011750A1 (en) * | 2004-07-27 | 2006-02-02 | C & C Research Laboratories | Tetrahydro-beta-carbolinone derivatives and process for preparing the same |
US7772245B2 (en) * | 2005-02-14 | 2010-08-10 | Miikana Therapeutics, Inc. | Inhibitors of histone deacetylase |
MX2009008507A (es) * | 2007-02-07 | 2009-08-20 | Astellas Pharma Inc | Derivado de acilguanidina. |
DE102007009264A1 (de) * | 2007-02-26 | 2008-08-28 | Ellneuroxx Ltd. | 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen |
RU2334747C1 (ru) * | 2007-04-05 | 2008-09-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
WO2009078423A1 (ja) * | 2007-12-18 | 2009-06-25 | National University Corporation University Of Toyama | アルドース還元酵素阻害活性を有する縮合三環化合物 |
RU2544856C2 (ru) * | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
CA2719412A1 (en) * | 2008-03-24 | 2009-10-01 | Medivation Technologies, Inc. | Pyrido[3,4-b]indoles and methods of use |
TW201038569A (en) * | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
-
2010
- 2010-09-23 US US13/498,099 patent/US20130137705A1/en not_active Abandoned
- 2010-09-23 WO PCT/US2010/050079 patent/WO2011038162A1/en active Application Filing
- 2010-09-23 CA CA2775129A patent/CA2775129A1/en not_active Abandoned
- 2010-09-23 BR BR112012006644A patent/BR112012006644A2/pt not_active IP Right Cessation
- 2010-09-23 CN CN2010800528027A patent/CN102711467A/zh active Pending
- 2010-09-23 AU AU2010298167A patent/AU2010298167B2/en not_active Ceased
- 2010-09-23 EP EP10819491.1A patent/EP2480079A4/en not_active Withdrawn
- 2010-09-23 JP JP2012531043A patent/JP5791611B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-04 US US13/734,873 patent/US20130123277A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2010298167B2 (en) | 2015-12-24 |
CN102711467A (zh) | 2012-10-03 |
EP2480079A1 (en) | 2012-08-01 |
US20130123277A1 (en) | 2013-05-16 |
US20130137705A1 (en) | 2013-05-30 |
WO2011038162A1 (en) | 2011-03-31 |
CA2775129A1 (en) | 2011-03-31 |
AU2010298167A1 (en) | 2012-04-12 |
JP5791611B2 (ja) | 2015-10-07 |
EP2480079A4 (en) | 2015-04-08 |
JP2013505946A (ja) | 2013-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012006644A2 (pt) | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit | |
BR112012006648A2 (pt) | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica e kit | |
BR112012006640A2 (pt) | composto, composição farmacêutica, método de tratamento de um distúrbio cognitivo, distúrbiopsocótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit | |
BR112012006646A2 (pt) | composto, composição farmacêutica, método de tratamento de um distùrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit | |
BRPI0906244A2 (pt) | Composto, composição farmacêutica, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissores ou um distúrbio neuronal em um indivíduo, uso de um composto e kit | |
BRPI0906245A2 (pt) | Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit | |
BRPI0816582A2 (pt) | Composto, método para tratar um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou distúrbio neuronal em um indivíduo, composição farmacêutica, uso de um composto e kit | |
BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
BRPI1010798A2 (pt) | fechamento, aparelho de retenção, e método de uso do mesmo | |
BR112013022927A2 (pt) | composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição | |
BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
BRPI0810082A2 (pt) | 3-imidazolil-indóis para o tratamento de doenças proliferativas | |
BRPI1008383A2 (pt) | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto | |
BRPI0918693A2 (pt) | dispositivos para amostragem e métodos para concentração de microorganismos | |
BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
BRPI0820474A2 (pt) | método de tratamento de uma doença, uso de composto, e, composto | |
BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI1015014A2 (pt) | composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cognição | |
BR112012020585A2 (pt) | composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase | |
EP2174914A4 (en) | PROCESS FOR TREATING DIARSENIC TRIOXIDE | |
BRPI0908883A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
DK2164572T3 (da) | Carbamoyl-cyclohexaner til behandling af akut mani | |
BR112013012072A2 (pt) | derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos | |
BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law | ||
B25I | Requirement for requested change of headquarter |
Owner name: MEDIVATION NEUROLOGY, INC. (US) Free format text: A FIM DE ATENDER A ALTERACAO DE ENDERECO REQUERIDA ATRAVES DA PETICAO NO 18140006063 DE 13/03/2014, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA DEPOSITANTE E O NOME DA EMPRESA QUE TEVE SEU ENDERECO ALTERADO. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B25E | Requested change of name of applicant rejected |
Owner name: MEDIVATION NEUROLOGY, INC. (US) Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE ALTERACAO(OES) DE NOME CONTIDO(S) NA PETICAO 018140006063 DE 13/03/2014 EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2559 DE 21/01/2020. |